SRX3207
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression[1][2].
Product Specifications
CAS Number
2254693-15-5
UNSPSC
12352005
Target
PI3K; Syk
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/srx3207.html
Purity
98.50
Solubility
DMSO : 5 mg/mL (ultrasonic)
Smiles
O=C1C2=C(C(C3=CC=C(NC4=NC=CC(N5N=C(C)C(CN6CCC6)=C5)=N4)C=C3)=CS2)OC(N7CCOCC7)=C1
Molecular Formula
C29H29N7O3S
Molecular Weight
555.65
References & Citations
[1]Shweta Joshi, et al. Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020.|[2]Shweta Joshi, et al. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 Mar;19 (3) :755-764.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PI3Kα; PI3Kγ; PI3Kδ
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040198-500 1x 500 µL
Cytokeratin 18 (DA7), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
